Reducing fish seizures
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials
September 22, 2021
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials
Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline MAPS to Investigate
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 10 clinical sites
Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency Fragile x syndrome
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline Revive Therapeutics (RVV) is partnering with
Wesana Health Announces Definitive Agreement to Acquire PsyTech Inc. Former Chicago Blackhawks player Daniel Carcillo
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board Are psychedelics the future
Ground-breaking research to explore the potential for psilocybin to treat traumatic brain injury This Fall,
Mike Tyson says psychedelics saved his life, now he hopes they can change the world
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of